For sales

📢Highlights from the Week of 18th -25th August, 2025   in the world of pharma and healthcare! 🗞️👀

Highlights from the Week of 18th August, 2025 - 25th August, 2025 VYUHPHARMA IONIS FDA approves lonis's DAWNZERA as first RNA-targeted hereditary angioedema therapy; it shows significant and sustained attack rate reduction, with dosing every 4 or 8 weeks (FDA, Approval) (EC, Approval) Spring Works THERAPEUTICS EU grants marketing authorization to SpringWorks Therapeutics-Merck KGaA's OGSIVEO for adult desmoid tumours (EC, Approval) Madrigal Pharmaceuticals Madrigal receives European Commission approval for REZDIFFRA for MASH with moderate to advanced liver fibrosis (EC, Approval) ADVANZ & Aalvotech PHARMA Advanz Pharma and Alvotech gain European Commission approval for MYNZEPLI biosimilar to Eylea after confirmatory clinical equivalence Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.